Johnson & Johnson: Janssen prostate drug shows improvements.
(CercleFinance.com) - Johnson & Johnson's subsidiary Janssen-Cilag said on Friday that treatment with Zytiga (abiraterone acetate) plus prednisone showed clinically meaningful and statistically significant improvements in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Additional data from a pivotal Phase clinical trial showed that the combination, associated with androgen deprivation therapy, demonstrated improvements in patients with newly diagnosed, high-risk, metastatic hormone-sensitive prostate cancer (mHSPC), compared to androgen deprivation therapy alone.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Additional data from a pivotal Phase clinical trial showed that the combination, associated with androgen deprivation therapy, demonstrated improvements in patients with newly diagnosed, high-risk, metastatic hormone-sensitive prostate cancer (mHSPC), compared to androgen deprivation therapy alone.
Copyright (c) 2017 CercleFinance.com. All rights reserved.